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Adenosine and its ‘R,‘- and ‘P-site analogs, N6-phenylisopropyladenosine and 2’-deoxyadenosine, stimulate. 
like insulin, lipoprotein lipase (LPL) activity in adipose tissue, an effect which is suppressed by cyclohexi- 
mide. However, adenosine and its analogs do not potentiate the effects of submaximal insulin concentra- 
tions. As addition of cyclic AMP phosphodiesterase inhibitors abolishes the LPL stimulatory effects of insu- 
lin, adenosine and its analogs, this study suggests that these LPL effects are mediated through common 
mechanisms which are likely a decrease in cyclic AMP and an increase in LPL biosynthesis. 
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1. INTRODUCTION 
Adenosine elicits some insulin-like effects on 
adipose tissue metabolism [11. In fact, like insulin, 
adenosine reduces the responsiveness of rat 
adipocytes to different lipolytic hormones [2,3]. 
As in the case of insulin, these effects seem related 
to a decrease in intracellular cyclic AMP level since 
adenosine, like insulin [4,5], stimulates cyclic 
AMP phosphodiesterase [6] and inhibits adenylate 
cyclase [7]. It is well established that the adenosine- 
effect on adenylate cyclase involves the binding of 
adenosine to two distinct specific sites: one, Ri- 
site, is located on the external side of the plasma 
membrane and has high affinity for adenosine, 
whereas the other, called the P-site, is located on 
the inner surface of the plasma membrane and 
binds adenosine with lower affinity [7-91. 
Another important effect of insulin on adipose 
tissue metabolism is to stimulate lipoprotein lipase 
(LPL) activity [lo, 1 l] and it has been suggested 
that part of this effect could be related to a 
decrease in adipose tissue cyclic AMP level [ 12,131. 
We have shown that adenosine and its catabolite 
inosine also increase the LPL activity of isolated 
adipocytes [14]. In the same study, we also found 
that theophylline, a potent inhibitor of cyclic AMP 
phosphodiesterase [ 151 and of adenosine-binding 
to the Ri-site [7], decreases LPL activity, an effect 
which appears unrelated to the adenosine an- 
tagonistic action of theophylline [ 141. 
The aim of this study was to determine whether 
the LPL stimulation induced by adenosine in 
adipose tissue was a Ri- or P-site-mediated effect. 
The effects of adenosine were therefore compared 
with those of the Ri-site and P-site adenosine 
analogs, N6-phenylisopropyladenosine (PIA) and 
2 ’ -deoxyadenosine (DXA), respectively, using 
conditions under which adenosine deaminase is in- 
hibited by deoxycoformycin [ 161. Moreover, to 
determine whether a common mechanism may be 
involved in the adenosine and insulin effects on 
LPL, the role played by protein synthesis and 
cyclic AMP in these effects was also examined by 
testing the influence of cycloheximide and 
phosphodiesterase inhibitors on the abilities of 
adenosine and insulin to stimulate LPL activity. 
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2. MATERIALS AND METHODS 
Porcine insulin (Actrapid, 40 IU/ml) and 
theophylline were purchased from Novo (France) 
and Merck (FRG) respectively. N6-(L-Phenyliso- 
propyl)adenosine (PIA) and adenosine deaminase 
were from Boehringer Mannheim (FRG). 
Adenosine, 2’-deoxyadenosine, cycloheximide and 
trioleylglycerol were obtained from Sigma (USA) 
and tri[l-‘4C]oleylglycerol (50 mCi/mmol) from 
the Radiochemical Centre (Amersham). Ro 20-1724 
and 2’-deoxycoformycin were generous gifts of 
Hoffman La Roche (Basel) and Substantia Labo- 
ratories (France), respectively. All other chemicals 
were of analytical grade. 
Male Wistar rats (140 f 20 g) were fasted over- 
night before killing. Epididymal fat pads were 
quickly removed, washed, cut into small pieces and 
incubated (200 mg/ml) under OZ/COZ (9515; v/v) 
in Krebs-Ringer bicarbonate buffer (pH 7.4) added 
or not with the compounds to be tested and con- 
taining 1.25 mM calcium, 5 mM glucose, 
20 mg/ml dialysed bovine albumin (fraction V), 
400 nM dexamethasone, 2 U/ml heparin [17] and 
an amino acid mixture (final concentrations 
390 mM) corresponding to the amino acid com- 
position of rat plasma [18]. 
After a 2 h incubation at 37°C (corresponding 
to the optimal conditions for insulin action) 
adipose tissue fragments were separated from the 
incubation buffer, homogenized at 4°C in 50 mM 
NH4OH-NH4Cl buffer (pH 8.6) and centrifuged at 
4°C. The clear supernatant was used for LPL 
assay which was performed according to a 
modification of the procedure in [ 191 as previously 
described [111. LPL activity was expressed as pmol 
14C free fatty acids (FFA) released/g fat pad per h. 
Each value is the mean + SE of 3-4 experiments 
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Fig.l. Stimulation of adenosine, deoxyadenosine and PIA-stimulated adipose tissue LPL activity by insulin. The values 
are means + SE of 3 separate experiments as described in section 2. C, control; D, deoxycoformycin (IOpM); A, 
adenosine (1OpM); DXA, deoxyadenosine (1OpM); ADA, adenosine deaminase (40 mU/ml); PIA, phenyliso- 
propyladenosine (0.1 pM). 
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performed in triplicate. The statistical differences 
were calculated by Student’s t-test: p values equal 
to or less than 0.02 were considered significant. 
Table 1 
Influence of cycloheximide on the stimulatory effects of 
insulin and adenosine on adipose tissue LPL activity 
Lipoprotein lipase activity 
&mol FFA. h-’ .g-’ wet wt) 
No With 
cycloheximide cycloheximide 
(36 rM) 
Control 11.3 k 0.7 11.7 k l.oa 
Insulin (9 mu/ml) 23.1 f 1.4b 11.4 + 1.0” 
Adenosine (10 /IM) 15.3 k 0.8b 11.1 * 0.7” 
a Non-significant compared to control 
bp < 0.001 compared to control 
Incubations were performed as described in section 2. 
Each value represents the mean -t SE of 3 incubations 
3. RESULTS 
As shown in fig.1 and tables 1 and 2, the 
magnitude of the LPL stimulation induced by in- 
sulin (9 mu/ml) was unchanged (loo-125% over 
basal values) under all experimental conditions. 
To avoid possible interference of endogenous 
adenosine deaminase on the effects of adenosine 
(10pM) and DXA (10pM) on LPL, these effects 
were studied in the presence of 2’-deoxycoformy- 
tin (lOpM), a potent inhibitor of adenosine 
deaminase [16]. As seen in fig. 1, addition of 
2’-deoxycoformycin slightly increased (27%) the 
basal LPL activity, an effect which could be due 
either to accumulation of endogenous adenosine 
[14] or to 2’-deoxycoformycin per se. Fig. 1 show- 
ed that adenosine and DXA increased significantly 
LPL activity (34.5% with adenosine and 49.5% 
with DXA), but the magnitude of each of these ef- 
fects was not statistically different from the other. 
It must be noted that the adenosine ffect observed 
here was lower than that previously reported by us 
[ 141. This difference could be explained by the fact 
that, in the latter studies, isolated fat cells were us- 
Table 2 
Influence of Ro 20-1724 and theophylline on the stimulatory effects of insulin, adenosine and 
2’ -deoxyadenosine on adipose tissue lipoprotein lipase activity 
Lipoprotein lipase activity &mol FFA. h-r .g-’ wet wt) 
No phosphodiesterase With Ro 20-1724 With theophylline 
inhibitors (1 mM) (5 mM) 
Control 
Insulin (9 mu/ml) 
2’-Deoxycoformycin (10 PM) 
2 ’ -Deoxycoformycin (10 PM) 
+ adenosine (10 PM) 
2 ’ -Deoxycoformycin (10 pM) 
+ 2’-deoxyadenosine 
(10 PM) 
9.1 * 0.37 7.4 + 0.5”” 4.7 + 0.2”” 
20.4 f 1.2aa 10.5 + 0.6bbdd 4.6 f 0.3bbd 
11.5 + 0.4a” 8.7 4 0.4CCd 
15.8 zk I.lCc 8.4 +- 0.6d - 
15.9 f 0.6”’ 8.0 k 0.4d - 
a Compared to control 
b Compared to insulin 
’ Compared to deoxycoformycin 
d Compared to Ro 20-1724 or theophylline 
One symbol: non-significant; two symbols: p < 0.001 
Incubations were performed as described in section 2. Each value represents the mean + SE of 3 
incubations 
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ed instead of whole adipose tissue fragments and 
that no adenosine deaminase inhibitor was includ- 
ed, allowing to consider the possibility that part of 
the observed effect could be due to inosine [14]. 
In the presence of 9 mu/ml insulin, which is a 
submaximal concentration [20], addition of 10 ,uM 
adenosine or DXA did not result in a further in- 
crease in LPL activity (fig. l), a finding which sug- 
gests that a common mechanism is involved in the 
effects of insulin and these nucleotides on LPL. 
As recent experiments howed that the insulin 
effect on adipose tissue LPL resulted, at least in 
part, from an increased post-transcriptional syn- 
thesis of the enzyme, the LPL responses to 
adenosine and insulin were compared in the 
presence of cycloheximide (36pM). As shown in 
table 1, cycloheximide completely prevented the ef- 
fect of adenosine on LPL and, as expected from 
previous experiments from this laboratory [l 11, the 
effect of insulin. 
In the next experiments, the effects of the Ri-site 
analog of adenosine, PIA (0.1 PM), on LPL were 
studied under the same experimental conditions as 
above, except that 2’-deoxycoformycin was 
replaced by adenosine deaminase to prevent the 
possible interference of endogenous adenosine 
(fig.1). Confirming previous observations [14], ad- 
dition of adenosine deaminase alone induced a 
34% increase in the basal LPL activity, an effect 
which, as shown previously, can be accounted for 
by inosine [14]. Addition of PIA resulted in a fur- 
ther increase of the LPL activity (24% over the ac- 
tivity found in the presence of adenosine 
deaminase alone, p < O.OOl), but, like adenosine 
and DXA, did not further enhance the magnitude 
of the LPL stimulation induced by insulin under 
these conditions (fig. 1). 
To investigate the possible role of cyclic AMP in 
the effects described above, the influence of in- 
sulin, adenosine and DXA on LPL was reexam- 
ined in the presence of a selective inhibitor of cyclic 
AMP phosphodiesterase, Ro 20-1724 [21], which 
does not interact with the binding of adenosine to 
its Ri-sites [7]. As shown in table 2, addition of 
Ro 20-1724 alone (1 mM) resulted in a 26% 
decrease in the basal LPL activity. Interestingly, 
when insulin was added in combination with 
RO 20-1724, the ability of insulin to stimulate LPL 
was considerably reduced, falling from 125% 
stimulation in the absence to 45% stimulation in 
the presence of Ro 20-1724. When another 
phosphodiesterase inhibitor, theophylline [ 151, 
was added in place of Ro 20-1724, about the same 
results were found except that no stimulation at all 
was observed in the presence of the hormone. As 
also shown in table 2, addition of Ro 20-1724 also 
completely suppressed the ability of either 
adenosine or DXA to stimulate adipose tissue LPL 
activity. 
4. DISCUSSION 
It is now well established that in several tissues, 
including adipose tissue, the purine substituted 
adenosine analog, PIA, binds to specific sites 
located on the cell surface and called the Ri-sites, 
whereas the ribose-modified adenosine analog, 
DXA, binds to intracellular sites, the P-sites [7]. 
Binding of these analogs to their respective sites 
results in adenylate cyclase inhibition [7] and, con- 
sequently, in a reduction of the intracellular cyclic 
AMP level. Like insulin which also decreases cyclic 
AMP level in adipose tissue [4], adenosine and its 
Ri- and P-site analogs, PIA and DXA, were found 
to increase adipose tissue LPL activity. Since cyclic 
AMP has been suggested to play a role in the 
regulation of LPL in adipose tissue [ 121, these find- 
ings raise two questions. (i) Is LPL stimulation in- 
duced by insulin, adenosine, PIA and DXA the 
consequence of cyclic AMP reduction induced by 
these compounds? (ii) Because adenosine exerts 
other insulin-like effects and sensitizes the fat cells 
to some actions of insulin [ 1,221, does endogenous 
adenosine play a role in the LPL stimulation in- 
duced by insulin? 
The present data showing that the insulin- and 
the adenosine- (or adenosine analog-) effects on 
LPL are suppressed or severely reduced in the 
presence of potent inhibitors of cyclic AMP 
phosphodiesterase strongly suggest that cyclic 
AMP is indeed involved in the mechanism by 
which both insulin and adenosine promote LPL 
activity in adipose tissue. However, the fact that 
the LPL response to adenosine is suppressed by 
cycloheximide also suggests that adenosine, like in- 
sulin [23], promotes the post-transcriptional 
biosynthesis of LPL. It cannot be excluded that 
this effect on the enzyme biosynthesis may be in- 
directly linked to decreased cyclic AMP consider- 
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ing the important role played by phosphoryla- 
tion/dephosphorylation processes in the control of 
protein synthesis initiation [24]. 
On the other hand, this study suggests that en- 
dogenous adenosine has probably no significant 
influence on the insulin action on LPL. In fact the 
magnitude of the LPL stimulation induced by a 
submaximal concentration of insulin [20] was (i) 
unaltered whether studied in the absence or 
presence of adenosine deaminase or deoxycofor- 
mycin and (ii) not additive with the effects of ex- 
ogenous adenosine or analogs. 
The importance of adenosine in the control of 
adipose tissue metabolism has already been 
documented in several previous reports. In fact, 
adenosine has been shown to increase the sensitivi- 
ty of the glucose transport system and of lipid 
biosynthesis to insulin in fat cells [22], two effects 
which do not seem to be entirely accounted for by 
a reduction in cyclic AMP biosynthesis. Moreover, 
adenosine, through binding to Ri-sites, inhibits, 
like insulin [4], adenylate cyclase and lipolysis [ 1,7] 
and, as recently shown by one of us [25], complete- 
ly masks the antilipolytic effect of agents inhibiting 
adenylate cyclase such as the cz2-adrenergic compo- 
nent of catecholamines. Finally, like insulin again 
[5], adenosine stimulates cyclic AMP phosphodies- 
terase activity in adipose tissue [6], an effect which 
seems to result from the selective stimulation of the 
low K,,, membrane-bound enzymic isoform [26]. 
The present findings of increased LPL aactivity by 
adenosine and its Ri- and P-site analogs provide an 
additional argument in favour of a potential role 
played by adenosine in the control of adipose 
tissue metabolism. 
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